NeoSync, based in Boston, MA, is a clinical-stage company developing NEST®, its proprietary non-invasive neuromodulation platform for Major Depressive Disorder and other CNS diseases. NEST (NeoSync-EEG Synchronized TMS) delivers low-energy, alternating magnetic field stimulation in daily 30-minute sessions that are personalized to a patient’s individual alpha brain frequency as measured by a brief EEG. The company is led by President and CEO Kate Rumrill. NeoSync completed a $13M Series D financing. The company intends to use the funds to support a planned registration study of NEST in patients with treatment-resistant depression (TRD) and to prepare for future commercial release. The technology positions synchronized TMS (sTMS) as a gentle, personalized neuromodulation approach.

Total raised

$13M

Funding rounds

1

Latest round

Series D

Latest activity

Aug 2017